Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
CRB-701
/
CSPC Pharma, Corbus Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
CRB-701
/
CSPC Pharma, Corbus Pharma
Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.
(Hall A; Poster Bd #: 296) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2122;
SYS6002 (CRB-701) demonstrates promising anti-tumor activity with a well-tolerated safety profile in patients with advanced nectin-4 positive solid tumors. Dose escalation at 4.5 mg/kg Q3W and dose expansion at 3.6 mg/kg Q3W are ongoing.
||||||||||
CRB-701
/
CSPC Pharma, Corbus Pharma
Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).
(Level 1, West Hall; Poster Bd # H7) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_579;
Continued development of SYS6002 (CRB-701) as both a monotherapy and in combination are planned. Clinical trial information: SYS6002-001.
||||||||||
CRB-701
/
CSPC Pharma, Corbus Pharma
Development of CRB-701 (SYS6002): A novel site-specific, Nectin-4 targeting ADC.
(LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_610;